Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 201–300 of 1,001
The steatotic liver disease burden paradox: unravelling the key role of alcohol
Torp, N., Israelsen, M. E., & Krag, A. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01022-y · Cited by 46
Țâru, M.-G., Leucuta, D.-C., Lupșor‐Platon, M., Turco, L., Ferri, S., Hashim, A., Orasan, O. H., Procopeț, B., Ştefănescu, H., Morelli, M. C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001190 · Cited by 51
Cuthbertson, D. J., Keating, S. E., Pugh, C. J. A., Owen, P. J., Kemp, G. J., Umpleby, M., Geyer, N. G., Chinchilli, V. M., & Stine, J. G. (2024) · Liver International · doi:10.1111/liv.15947 · Cited by 38
“…this highly significant unmet clinical need, we conducted a post hoc analysis of our three randomised controlled studies of aerobic exercise (12–20-week duration), 14,22,23 pooling data to quantify changes in MRI-measured liver fat, cardiorespiratory fitness (V̇O 2 peak), liver biochemistry…”
Gurun, M., Brennan, P., Handjiev, S., Khatib, A., Leith, D., Dillon, J. F., & Byrne, C. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299507 · Cited by 40
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD
Petta, S., Armandi, A., & Bugianesi, E. (2024) · Liver International · doi:10.1111/liv.16133 · Cited by 47
“If advanced fibrosis bears the risk for liver-related events and all-cause mortality [13, 14], the complex picture of metabolic syndrome is responsible for the clinical burden in patients with low fibrosis stages, but across all spectrum of MASLD, including cirrhosis.”
Liu, W., Huang, S., Ji, H., Kim, S. U., Yip, T. C., Wong, G. L., Petta, S., Tsochatzis, E. A., Nakajima, A., Bugianesi, E., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.034 · Cited by 49
Self-citationGawrieh, S., Lake, J. E., Debroy, P., Sjoquist, J. A., Robison, M., Tann, M. A., Akisik, F. M., Bhamidipalli, S. S., Saha, C., Zachary, K. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000313 · Cited by 40
Self-citationNonalcoholic Steatohepatitis — Opportunities and Challenges
García–Tsao, G. (2021) · New England Journal of Medicine · doi:10.1056/nejme2110989 · Cited by 40
Hadefi, A., Arvanitakis, M., Trépo, E., & Zelber‐Sagi, S. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12443 · Cited by 42
“NAFLD is a spectrum of liver diseases ranging from liver steatosis to non‐alcoholic steatohepatitis (NASH), and fibrosis, which may lead to cirrhosis and hepatocellular carcinoma.(7) Furthermore, NAFLD is associated with an increased risk of incident T2DM, chronic kidney disease, extrahepatic cancers, and cardiovascul…”
BackgroundDigital pathology for nonalcoholic steatohepatitis assessment
Sanyal, A. J., Jha, P., & Kleiner, D. E. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00843-7 · Cited by 40
“Fibrosis is the most robust prognosis marker and arguably the most important end point in clinical trials 23,108 .”
Self-citationHepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Friedman, S. L. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0240 · Cited by 42
“This finding is supported by a significant longitudinal study from the NASH CRN, which followed almost 1,800 patients for 10 years and established the importance of fibrosis as a risk factor for death from any cause, hepatic decompensation, and HCC [52].”
ResultA roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 41
“…of morbidity and mortality in MASLD (liver-related complications and death, cardiovascular disease, and hepatic and extrahepatic malignancies), with prognosis correlating closely with the fibrosis stage, for example, from absence of fibrosis to cirrhosis in the F0 to F4 staging system 24 .”
Nonalcoholic fatty liver disease and non-liver comorbidities
Manikat, R., & Nguyen, M. H. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0442 · Cited by 46
Borisov, A. N., Kutz, A., Christ, E., Heim, M. H., & Ebrahimi, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad249 · Cited by 40
Biciusca, T., Stan, S. I., Bălteanu, M. A., Cioboată, R., Ghenea, A. E., Dănoiu, S., Bumbea, A. M., & Biciuşcă, V. (2023) · Diagnostics · doi:10.3390/diagnostics13213316 · Cited by 45
“In patients with NAFLD-related cirrhosis, however, liver complications are the main cause of death [37,38].”
BackgroundThe Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, M., Uribe, J., Olvares, N., Huerta, P., Cabrera, D., & Romero‐Gómez, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101501 · Cited by 41
“Since liver fi brosis is the main prognostic factor of liver-related complications and death, severity assessment is focused on grading liver fi brosis [62].”
BackgroundBejjani, A. C., & Finn, R. S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02605 · Cited by 36
Kaya, E., & Yilmaz, Y. N. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221139650 · Cited by 41
Huang, D. Q., Wilson, L., Behling, C. A., Amangurbanova, M., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001015 · Cited by 42
Self-citationThe global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
Chew, N., Mehta, A., Goh, R. J. L., Koh, J., Chen, Y., Chong, B., Chan, M. Y., Khan, M. S., Muthiah, M. D., Butler, J., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01220-4 · Cited by 45
Self-citationKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Self-citationScreening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
Canivet, C. M., & Boursier, J. (2022) · Diagnostics · doi:10.3390/diagnostics13010091 · Cited by 41
Limei, E., Zhang, S., & Jiang, X. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-25258-4 · Cited by 37
Carr, R. M., Li, Y., Chau, L., Friedman, E. S., Lee, J., Adorini, L., Erickson, M., Zaru, L., Shringarpure, R., MacConell, L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000474 · Cited by 36
“[3,5,6] While the clinical diagnosis of cirrhosis is typically reliably established noninvasively by a combination of clinical symptoms and signs, radiology, elastography, and liver function tests, the discernment of non-cirrhotic NASH is more challenging, often requiring invasive liver biopsy to…”
BackgroundEffects of curcumin on non-alcoholic fatty liver disease: A scientific metrogy study
Li, X., Chen, W., Ren, J., Gao, X., Zhao, Y., Song, T., Fu, K., Zheng, Y., & Yang, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155241 · Cited by 35
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies
Ganne‐Carrié, N., & Nahon, P. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.030 · Cited by 38
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 40
Self-citationAhmad, M. I., Khan, M. U., Kodali, S., Shetty, A., Bell, S. M., & Victor, D. W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s344559 · Cited by 38
Ebrahimi, F., Simon, T. G., Hagström, H., Söderling, J. K., Wester, A., Roelstraete, B., & Ludvigsson, J. F. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.05.013 · Cited by 41
Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis
Rivera‐Esteban, J., Manzano-Núñez, R., Broquetas, T., Serra-Matamala, I., Bassegoda, O., Soriano-Varela, A., Espín, G., Castillo‐Iturra, J., Bañares, J., Carrión, J. A., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100574 · Cited by 34
“30 Yet, two observations prevent us from drawing clear conclusions.”
Ballestri, S., Mantovani, A., Girolamo, M. D., Baldelli, E., Capitelli, M., & Lonardo, A. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.23 · Cited by 36
Takahashi, K., Kawanaka, M., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Morishita, A., Munekage, K., et al. (2023) · Nutrients · doi:10.3390/nu15092014 · Cited by 42
Ünalp–Arida, A., & Ruhl, C. E. (2024) · Hepatology · doi:10.1097/hep.0000000000001211 · Cited by 41
Wang, G., Duan, J., Pu, G., Ye, C., Li, Y., Xiu, W., Xu, J., Liu, B., Zhu, Y., & Wang, C. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166413 · Cited by 37
Truong, E., GORNBEIN, J. A., Yang, J. D., Noureddin, N., Harrison, S. A., Alkhouri, N., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.003 · Cited by 35
Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions
Kadi, D., Loomba, R. S., & Bashir, M. R. (2024) · Radiology · doi:10.1148/radiol.222695 · Cited by 35
Self-citationPuengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“Intrinsic (e.g. genetics, sex, age) and extrinsic (e.g. lifestyle factors, dietary habits, gut microbiota) risk factors modulate fibrosis evolution to liver cirrhosis, which is associated with the development of hepatocellular carcinoma (HCC) [6,7].”
Koutoukidis, D. A., Yen, S., Castro, P. G., Misheva, M., Jebb, S. A., Aveyard, P. N., Tomlinson, J., Mózes, F. E., Cobbold, J., Johnson, J. S., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2392864 · Cited by 33
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
Geng, Y., & Schwabe, R. F. (2025) · Hepatology · doi:10.1097/hep.0000000000001386 · Cited by 41
ACG Clinical Guideline: Hepatic Encephalopathy
Bajaj, J. S., Jakab, S., Jesudian, A. B., Rahimi, R. S., Duarte‐Rojo, A., Chen, P.-H., Wong, R. J., Tapper, E. B., & Tandon, P. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003899 · Cited by 39
Zheng, Y., Xie, L., Yang, D., Luo, K., & Li, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154721 · Cited by 33
Alqahtani, S. A., Chan, W., & Yu, M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.019 · Cited by 32
Romero‐Gómez, M., Armstrong, M. J., Funuyet‐Salas, J., Mangla, K. K., Ladelund, S., Sejling, A., Shrestha, I., & Sanyal, A. J. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17598 · Cited by 34
Self-citationChen, T., Dalton, G. D., Oh, S., Maeso‐Díaz, R., Du, K., Meyers, R. A., Guy, C. D., Abdelmalek, M. F., Henao, R., Guarnieri, P., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.12.008 · Cited by 35
Self-citationHu, J., Cai, X., Zhu, Q., Heizhati, M., Wen, W., Luo, Q., Hong, J., Dang, Y., Yang, W., & Li, N. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s408722 · Cited by 32
Ratziu, V., Yilmaz, Y. N., Lazas, D. J., Friedman, S. L., Lackner, C., Behling, C. A., Cummings, O. W., Chen, L., Petitjean, M. M., Gilgun‐Sherki, Y., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000980 · Cited by 35
“[29,30] While histological classifications of fibrosis are predictive of liver-related events and liver-related mortality, [31] their use in trials testing antifibrotic agents has several shortcomings.”
Self-citationAnania, F. A., Hager, R., Higgins, K. M., Makar, G. A., Siegel, J. N., & Tran, T. T. (2025) · Hepatology · doi:10.1097/hep.0000000000001509 · Cited by 31
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Díaz, L. A., Thiele, M. S., Louvet, A., Lee, B. P., Ajmera, V. H., Tavaglione, F., Hsu, C. L., Huang, D. Q., Pose, E., Bataller, R. A., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01120-5 · Cited by 38
Self-citationMASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
Self-citationAcute-on-Chronic Liver Failure
Bajaj, J. S., Wong, F. S.-H., Kamath, P. S., Lai, J. C., & O’Leary, J. G. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001748 · Cited by 31
Younossi, Z. M., Alkhouri, N., Cusi, K., Isaacs, S. D., Kanwal, F., Noureddin, M., Loomba, R. S., Ravendhran, N., Lam, B. P., Nader, K., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17346 · Cited by 33
Self-citationPickhardt, P. J., Blake, G. M., Kimmel, Y., Weinstock, E., Shaanan, K., Hassid, S., Abbas, A., & Fox, M. A. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.23.29651 · Cited by 31
Large-scale identification of undiagnosed hepatic steatosis using natural language processing
Schneider, C. V., Li, T., Zhang, D., Mezina, A. I., Rattan, P., Huang, H. Y. R., Creasy, K. T., Scorletti, E., Zandvakili, I., Vujković, M., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102149 · Cited by 31
“27 Applying NLP, the algorithm led to the identi fi cation of steatosis in 22% of all evaluated biopsy cases and 25% of all evaluated images that included the liver.”
MethodYu, J., Li, D., You, Y., Yu, J., Jiang, W., Liu, Y., Zeng, R., Wan, Z., Yi, L., & Liao, X. (2023) · BMC Medicine · doi:10.1186/s12916-023-03080-6 · Cited by 34
“Similar to findings from previous studies, individuals with MAFLD and fibrosis had a higher risk of cardiac events and nonhe-patic mortality [32, 33].”
ResultScreening for liver fibrosis: lessons from colorectal and lung cancer screening
Thiele, M. S., Kamath, P. S., Graupera, I., Castells, A., de Koning, H. J., Serra‐Burriel, M., Lammert, F., & Ginès, P. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00907-2 · Cited by 34
“A key rationale for screening is therefore to detect moderate or severe liver fibrosis before cirrhosis, when the 3–5-year risk of liver-related events is low 32–35 .”
Younossi, Z. M., Mangla, K. K., Berentzen, T. L., Grau, K., Kjær, M. S., Ladelund, S., Nitze, L. M., Coolbaugh, C. L., Hsu, C.-Y., & Hagström, H. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000423 · Cited by 34
Minetti, E. T., Hamburg, N. M., & Matsui, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1469492 · Cited by 38
A new treatment and updated clinical practice guidelines for MASLD
Powell, E. E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01014-y · Cited by 32
“The risk of cirrhosis-related complications and liver disease mortality increases markedly with the advent of advanced fibrosis 4 and MASLD is the fastest growing indication for liver transplantation 5 .”
Hong, S. E., Mun, S. J., Lee, Y. J., Yoo, T., Suh, K., Kang, K. W., Son, M. J., Kim, W. K., & Choi, M. (2025) · Nature Genetics · doi:10.1038/s41588-025-02237-8 · Cited by 45
“MASLD encompasses a spectrum of liver conditions ranging from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), with progression to cirrhosis and hepatocellular carcinoma in a subset of patients 1,2 .”
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 35
Gómez, E. V., Pirola, C. J., Sookoian, S. C., Wilson, L., Liang, T., & Chalasani, N. (2022) · Hepatology · doi:10.1002/hep.32491 · Cited by 33
Self-citationHepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Dahan, K. S. E., Daher, D., & Singal, A. G. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0247 · Cited by 33
“14 for F4 fibrosis.(40) A meta-analysis of 18 studies with 470,404 patients found a pooled annual incidence of 0.”
Fan, Z., Sun, X., Chen, X., Liu, H., Miao, X., Guo, Y., Xu, Y., Li, J., Zou, X., & Li, Z. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100805 · Cited by 35
“59 Our data show that CCL11 deletion, neutralisation, and antagonism are all met with attenuation of liver fi brosis in mice.”
Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
Valenzuela‐Vallejo, L., Sanoudou, D., & Mantzoros, C. S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050830 · Cited by 33
Natural history of NAFLD: knowns and unknowns
Tsochatzis, E. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00565-8 · Cited by 33
Evolving portal hypertension through Baveno VII recommendations
Mendizábal, M., Cançado, G. G. L., & Albillos, A. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101180 · Cited by 35
“In this regard, it is important to highlight that the risk of decompensation in cirrhosis varies among the different etiologies, being 4 − 5-fold higher in alcohol-related than in metabolic associated fatty liver disease [37].”
Albert, S. G., & Wood, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108777 · Cited by 36
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis
Ma, F., Longo, M., Meroni, M., Bhattacharya, D., Paolini, E., Mughal, S., Hussain, S., Anand, S. K., Gupta, N., Zhu, Y., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.020 · Cited by 29
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Bai, W., & Zhu, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1720780 · Cited by 36
“The transition from simple steatosis to progressive MASH is orchestrated by a self-perpetuating cycle of metabolic insult, in fl ammatory ampli fi cation, and microenvironmental remodeling, ultimately driving irreversible hepatic fi brosis (1, 9, 10).”
Esteatohepatitis no alcohólica
Romero‐Gómez, M. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.06.017 · Cited by 36
Lee, S. W., Huang, D. Q., Bettencourt, R., Ajmera, V. H., Tincopa, M. A., Noureddin, N., Amangurbanova, M., Siddiqi, H., Madamba, E. V., Majzoub, A. M., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17783 · Cited by 32
Self-citationMarchianò, S., Biagioli, M., Bordoni, M., Morretta, E., Giorgio, C. D., Vellecco, V., Roselli, R., Bellini, R., Massa, C., Cari, L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031241 · Cited by 31
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 38
Díaz, L. A., Ajmera, V. H., Arab, J. P., Huang, D. Q., Hsu, C. L., Lee, B. P., Louvet, A., Thiele, M. S., Tavaglione, F., Tincopa, M. A., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.017 · Cited by 34
Self-citationJackson, E., Dennis, A., Alkhouri, N., Samala, N. R., Vuppalanchi, R., Sanyal, A. J., Muthiah, M. D., Banerjee, R., & Banerjee, A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03654-2 · Cited by 31
“Continuous cT1 was associated with higher rates of liver events increased risk of both major adverse cardiovascular and liver events; the latter include variceal hemorrhage, ascites and encephalopathy 6 , and hepatic cancer 7 and liver transplantation 8,9 .”
Self-citationCuthbertson, D. J., Kennedy, O. J., Bilson, J., Hydes, T., Targher, G., Glyn‐Owen, K., Buchanan, R. M., Roderick, P. J., & Byrne, C. D. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156306 · Cited by 35
Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
Mancina, R. M., Valenti, L. V. C., & Romeo, S. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01394-8 · Cited by 32
Specific Challenges in Geriatric Cirrhosis and Hepatic Encephalopathy
Bajaj, J. S., Gentili, A., Wade, J. B., & Godschalk, M. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.035 · Cited by 35
Chhatwal, J., Dalgic, O. O., Chen, W., Samur, S., Bethea, E. D., Xiao, J., Hur, C., Corey, K. E., & Loomba, R. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.30426 · Cited by 30
Self-citationHuman Gut Microbiota in Cardiovascular Disease
Ronen, D., Rokach, Y., Abedat, S., Qadan, A., Daana, S., Amir, O., & Asleh, R. (2024) · Comprehensive physiology · doi:10.1002/cphy.c230012 · Cited by 33
Zhang, G. Y., & Brandman, D. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.6431 · Cited by 27
The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints
Tapper, E. B., Goldberg, D. S., Parikh, N. D., Terrault, N. A., Welch, N., Sharpton, S. R., Hameed, B., Khalili, M., Stolz, A., Verna, E. C., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002953 · Cited by 30
“Thesefactorsin-fl uence the risk of competing extrahepatic adverse events and may alter the patterns and risk of decompensation events (3,4).”
Self-citationDysfunctional VLDL metabolism in MASLD
Marigorta, U. M., Millet, Ó., Lu, S. C.-L., & Mato, J. M. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00018-1 · Cited by 33
“…fi cant fi brosis ( fi brosis stage 2 or higher) 40 , a condition referred to as at-risk MASH due to its association with elevated morbidity and mortality risk 41,42 , the authors included discovery ( n = 790) and validation ( n = 565) cohorts of liver biopsied individuals recruited internationally.”
BackgroundKaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 34
“Patients in this study with advanced fibrosis experienced an increased rate of liver-related events including hepatic decompensation, ascites, hepatic encephalopathy, hepato-cellular carcinoma (HCC), and the need for liver transplant [24 ].”
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
Noninvasive assessment of hepatic decompensation
Thiele, M. S., Johansen, S., Israelsen, M. E., Trebicka, J., Abraldeṣ, J. G., Ginès, P., & Krag, A. A. (2023) · Hepatology · doi:10.1097/hep.0000000000000618 · Cited by 33
“[3] 5] While diagnostic NITs for patients with suspected liver disease are often used sequentially along a health care pathway, secondary and tertiary care more often use NITs in parallel, looking for concordant results to support management decisions.”
Liver fibrosis phenotyping and severity scoring by quantitative image analysis of biopsy slides
Watson, A. J. R., Petitjean, L., Petitjean, M. M., & Pavlides, M. (2023) · Liver International · doi:10.1111/liv.15768 · Cited by 31
Epidemiology of NAFLD – Focus on diabetes
Younossi, Z. M., & Henry, L. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111648 · Cited by 30
Mittal, N., Siddiqi, H., Madamba, E. V., Richards, L., Bettencourt, R., Ajmera, V. H., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17997 · Cited by 30
“Patients with significant fibrosis (fibrosis stage 2 or higher, [≥F2]) 6 or advanced fibrosis (fibrosis stage 3 or higher, ≥F3) 7,8 face increased risks of morbidity and mortality.”
BackgroundSelf-citationBile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 33
Balcar, L., Krawanja, J., Scheiner, B., Paternostro, R., Simbrunner, B., Semmler, G., Jachs, M., Hartl, L., Stättermayer, A. F., Schwabl, P., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100682 · Cited by 32
Gairing, S. J., Schleicher, E. M., Galle, P. R., & Labenz, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000096 · Cited by 28
“[1] The incidence of HE is likely to rise in the future, as it is the most frequent first decompensation event in patients with NAFLD.[2] Clinical symptoms of HE range from subclinical alterations to coma.”
BackgroundIwata, A., Maruyama, J., Natsuki, S., Nishiyama, A., Tamura, T., Tanaka, M., Shichino, S., Seki, T., Komai, T., Okamura, T., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06357-5 · Cited by 25
“However, our RNA-seq analysis indicated that IL-4 and IL-13 expression was minimal in MASH liver (Supplementary Data 2).”
InfluentialDiagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 50
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Koenig, A. B., Tan, A., Abdelaal, H., Monge, F., Younossi, Z. M., & Goodman, Z. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18059 · Cited by 30
“204 Careful management of cardiovascular risk factors is needed to prevent coronary heart disease and stroke among patients with MASLD.”
BackgroundElevated GGT to HDL ratio as a marker for the risk of NAFLD and liver fibrosis
Xuan, Y., He, F., Liu, Q. F., Dai, D., Wu, D., Shi, Y., & Yao, Q. Z. (2025) · Scientific Reports · doi:10.1038/s41598-024-84649-w · Cited by 28
Vali, Y., van Dijk, A., Lee, J., Boursier, J., Ratziu, V., Yunis, C., Schattenberg, J. M., Valenti, L. V. C., Romero‐Gómez, M., Schuppan, D., et al. (2025) · Liver International · doi:10.1111/liv.16240 · Cited by 30
Jain, P., Jain, A., Deshmukh, R., Samal, P. K., Satapathy, T., & Ajazuddin, M. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102584 · Cited by 32
Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27
“…steatosis ( ≥ 5% of hepatocytes) with evidence of metabolic dysfunction A subset of MASLD where steatosis is accompanied by hepatic inflammation, ballooning due to cytoskeletal collapse (keratin-18 cleavage), apoptosis, necroptosis, and fibrosis associated with all-cause mortality (HR:6.8) [ 24].”
InfluentialMiao, L., Xu, J., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0015 · Cited by 27
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.